Restarting GLP-1 Treatment Post Tibial Fracture with Slow-Healing Eschar Wound
GLP-1 receptor agonists can be cautiously restarted after tibial fracture once the wound shows clear signs of healing progression, but the decision must weigh the increased nonunion risk against the substantial cardiovascular and mortality benefits, particularly in patients with diabetes or established cardiovascular disease.
Key Clinical Considerations
Wound Healing Status Assessment
Before restarting GLP-1 therapy, evaluate:
- Eschar characteristics: Stable, dry eschar without surrounding erythema, warmth, or purulent drainage
- Wound bed: Presence of granulation tissue beneath or around eschar edges
- Infection markers: Absence of systemic signs (fever, elevated WBC) and local infection
- Vascular status: Adequate perfusion to the affected limb (palpable pulses, capillary refill <3 seconds)
Fracture Healing Considerations
Critical Evidence on Nonunion Risk: Recent data reveals GLP-1 receptor agonists are associated with significantly higher nonunion rates after tibial plateau fractures 1. In a 2026 study, nonunion occurred in 5.4% of GLP-1 users versus 4.4% of matched controls at 1-year follow-up (Risk Ratio 1.2) 2. However, this must be balanced against a 50% reduction in cardiac arrest (0.8% vs 1.6%) and 45% reduction in all-cause mortality (4.4% vs 8.0%) in GLP-1 users 2.
Decision Algorithm for Restarting
Proceed with restart if:
- Fracture shows radiographic evidence of callus formation (typically 6-8 weeks post-injury)
- Wound demonstrates healing progression (granulation tissue, epithelialization at margins)
- Patient has diabetes with A1C >7% or established cardiovascular disease
- No signs of active infection
Delay restart if:
- Fracture shows no callus formation on serial radiographs
- Wound remains static or deteriorating
- Active infection present
- Patient is within first 4-6 weeks post-fracture
Consider alternative agents if:
- Patient is non-diabetic using GLP-1 solely for weight loss
- Significant concern for delayed union based on fracture pattern or patient factors
- Multiple risk factors for nonunion (smoking, NSAIDs, poor nutrition)
Practical Restart Protocol
Titration Strategy
When restarting, use gradual dose escalation to minimize gastrointestinal effects that could impact nutrition 3, 4:
For Semaglutide:
- Start 0.25 mg weekly × 4 weeks
- Advance to 0.5 mg weekly × 4 weeks
- Continue stepwise to maintenance dose
For Liraglutide:
- Start 0.6 mg daily × 7 days
- Increase by 0.6 mg increments weekly
- Target maintenance 1.8-3.0 mg daily
Monitoring Requirements
Fracture healing surveillance:
- Radiographs every 4-6 weeks until union confirmed
- Clinical assessment for pain, instability, or functional limitations
- Consider CT scan if plain films equivocal at 12-16 weeks
Wound monitoring:
- Weekly assessment until complete epithelialization
- Document wound measurements and characteristics
- Immediate evaluation if signs of infection develop
Metabolic optimization:
- Ensure adequate protein intake (1.2-1.5 g/kg/day) to support healing
- Vitamin D level >30 ng/mL
- Calcium supplementation if dietary intake inadequate
Special Populations
Diabetic Patients with Cardiovascular Disease
Strong recommendation to restart given proven cardiovascular benefits 3, 5. The LEADER trial demonstrated 22% reduction in cardiovascular death with liraglutide 3. The mortality benefit likely outweighs the modest increase in nonunion risk, particularly as nonunion can be managed with revision surgery while cardiovascular events may be fatal.
Non-Diabetic Patients Using GLP-1 for Weight Loss
Exercise greater caution. The risk-benefit ratio is less favorable when the drug is not providing glycemic or established cardiovascular protection 4, 6. Consider holding therapy until fracture union is radiographically confirmed (typically 12-16 weeks).
Patients with Renal Impairment
Most GLP-1 receptor agonists require no dose adjustment for renal function 3, 5. Liraglutide, semaglutide, and dulaglutide can be used without modification even with eGFR 15-29 mL/min/1.73 m² 5. Avoid exenatide if eGFR <30 mL/min/1.73 m² 5.
Common Pitfalls to Avoid
Do not:
- Restart at full maintenance dose—this increases gastrointestinal side effects that impair nutritional intake critical for healing
- Ignore the cardiovascular indication—in diabetic patients with established CVD, the mortality benefit is substantial and documented 3, 2
- Assume all GLP-1 agents are equivalent—semaglutide has longest half-life (1 week) and may have more prolonged effects on healing 6
- Neglect nutritional assessment—GLP-1-induced satiety can lead to inadequate protein/calorie intake during critical healing phase
Do:
- Document clear rationale for restart timing in medical record
- Engage in shared decision-making discussing both nonunion risk and cardiovascular/mortality benefits 7, 8
- Coordinate with orthopedic surgery regarding fracture healing status
- Consider wound care consultation for complex or stalled wounds
Infection Risk Considerations
Emerging evidence suggests GLP-1 receptor agonists may actually reduce infection-related complications. A 2026 analysis of ankle fracture ORIF patients showed 90-day composite infection/implant removal occurred in only 1.45% of GLP-1 users versus 6.26% of non-users (HR 0.34) 9. This protective effect persisted at 1 year (1.79% vs 11.92%, HR 0.42) 9. The mechanism may involve improved glycemic control and reduced inflammatory markers.
Perioperative Considerations for Future Procedures
If the patient requires subsequent surgery (hardware removal, nonunion repair), continue GLP-1 therapy perioperatively rather than routine discontinuation 10. Recent multidisciplinary consensus supports continuation with enhanced mitigation strategies (strict fasting adherence, consideration of gastric ultrasound, aspiration precautions) rather than blanket cessation 10, 11. The 2025 UK consensus specifically recommends patients "continue to take glucagon-like peptide-1 receptor agonists throughout the peri-operative period" 10.